| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.13 | 0.04 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.04 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.04 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |